



1624

Practitioner's Docket No. 49592 (71878)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: D. Williams et al.  
SERIAL NO.: 09/506,362 GROUP: 1624  
FILED: February 15, 2000 EXAMINER: J. Ford  
FOR: APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL

1. Transmitted herewith is a Supplemental Amendment for this application.

STATUS

2. Applicant is  
[ ] a small entity. A statement:  
[ ] is attached.  
[ ] was already filed.  
[X] other than a small entity.

RECEIVED

JAN 09 2003

TECH CENTER 1600/2900

EXTENSION OF TERM

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) — If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

FACSIMILE

- ☐ transmitted by facsimile to the Patent and Trademark Office.

*Susan M. Dillon*  
Signature

Date: January 2, 2003

Susan M. Dillon

(type or print name of person certifying)



#22

Docket No. 49592 (71878)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****APPLICANT:** D. Williams, et al.**RECEIVED****SERIAL NO.:** 09/506,362**ART UNIT:** 1624**JAN 09 2003****FILED:** February 15, 2000**EXAMINER:** J. Ford**TECH CENTER 1600/2900****FOR:** APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner of Patents and Trademarks  
Washington, DC 20231

Sir:

**SUPPLEMENTAL AMENDMENT**

This Supplemental Amendment is submitted following Applicants' response filed with the U.S. Patent Office on December 24, 2002, and further in response to the Office Action issued on September 25, 2002.

**REMARKS**

Applicants merely wish to enclose a clean copy of two enclosures which were provided with their earlier response. No new matter is added by virtue of the within Supplemental Amendment.

In particular, as part of their earlier response, Applicants offered certain results in tabular form which demonstrated the ability of the claimed compounds to induce apoptosis in additional cell lines such as prostate cancer (PC3) and ovarian carcinoma (OAW42), for example. Applicants merely wish to enclose a cleaner copy of that table.

Additionally, in further support of Applicants' arguments, the earlier response enclosed a copy of a paper entitled "Tumor selective G<sub>2</sub>/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine" (Xia et al., *PNAS*, June